ACA
Avoro Capital Advisors Portfolio holdings
AUM
$5.71B
This Quarter Return
+23.19%
1 Year Return
+11.37%
3 Year Return
+255.37%
5 Year Return
+558.9%
10 Year Return
+18,722.72%
AUM
$5.81B
AUM Growth
+$5.81B
(-18%)
Cap. Flow
-$1.94B
Cap. Flow
% of AUM
-33.49%
Top 10 Holdings %
Top 10 Hldgs %
69.35%
Holding
53
New
6
Increased
14
Reduced
8
Closed
9
Top Buys
| 1 |
United Therapeutics
UTHR
|
$433M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$104M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$98.8M |
| 4 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$83.7M |
| 5 |
Praxis Precision Medicines
PRAX
|
$68.7M |
Top Sells
| 1 |
IMMU
Immunomedics Inc
IMMU
|
$2.23B |
| 2 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$257M |
| 3 |
Iovance Biotherapeutics
IOVA
|
$94.5M |
| 4 |
Karyopharm Therapeutics
KPTI
|
$87.6M |
| 5 |
uniQure
QURE
|
$64.5M |
Sector Composition
| 1 | Healthcare | 97.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $996M | 17.15% | 4,535,000 +192,000 | +4% | +$42.2M |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $658M | 11.34% | 9,000,000 +1,350,000 | +18% | +$98.8M |
|
|
3
United Therapeutics
UTHR
$13.8B
| $433M | 7.45% | +2,850,000 | New | +$433M |
|
|
4
Iovance Biotherapeutics
IOVA
$807M
| $348M | 5.99% | 7,500,000 -2,036,039 | -21% | -$94.5M |
|
|
ARNA
5
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $322M | 5.54% | 4,190,000 +1,090,000 | +35% | +$83.7M |
|
6
Ascendis Pharma
ASND
$11.8B
| $300M | 5.17% | 1,800,000 | – | – |
|
7
Sarepta Therapeutics
SRPT
$1.78B
| $298M | 5.14% | 1,750,000 +75,000 | +4% | +$12.8M |
|
8
argenx
ARGX
$43.6B
| $265M | 4.57% | 902,500 | – | – |
|
9
Amicus Therapeutics
FOLD
$2.34B
| $208M | 3.58% | 9,000,000 -1,850,000 | -17% | -$42.7M |
|
|
XLRN
10
DELISTED
Acceleron Pharma Inc.
XLRN
| $198M | 3.42% | 1,550,000 +200,000 | +15% | +$25.6M |
|
11
Mersana Therapeutics
MRSN
$36.5M
| $181M | 3.12% | 6,800,000 | – | – |
|
12
BioMarin Pharmaceuticals
BMRN
$11.2B
| $145M | 2.49% | 1,650,000 -100,000 | -6% | -$8.77M |
|
13
Madrigal Pharmaceuticals
MDGL
$9.76B
| $136M | 2.35% | 1,225,000 +335,000 | +38% | +$37.2M |
|
14
Kura Oncology
KURA
$686M
| $131M | 2.25% | 4,000,000 +1,565,000 | +64% | +$51.1M |
|
15
PMV Pharmaceuticals
PMVP
$74.2M
| $131M | 2.25% | 2,350,267 +500,267 | +27% | +$27.8M |
|
|
16
Acadia Pharmaceuticals
ACAD
$4.38B
| $104M | 1.8% | +1,950,000 | New | +$104M |
|
17
Adverum Biotechnologies
ADVM
$64.6M
| $86.7M | 1.49% | 8,000,000 | – | – |
|
|
TRIL
18
DELISTED
Trillium Therapeutics Inc.
TRIL
| $85.3M | 1.47% | 5,800,000 +300,000 | +5% | +$4.41M |
|
|
CNST
19
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $85M | 1.46% | 2,950,000 -1,325,000 | -31% | -$38.2M |
|
|
DCPH
20
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $74.2M | 1.28% | 1,300,000 -520,000 | -29% | -$29.7M |
|
|
21
Praxis Precision Medicines
PRAX
$958M
| $68.7M | 1.18% | +1,545,495 | New | +$68.7M |
|
|
CBAY
22
DELISTED
Cymabay Therapeutics
CBAY
| $59.1M | 1.02% | 10,300,000 | – | – |
|
|
ISEE
23
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $50.1M | 0.86% | 7,250,000 | – | – |
|
24
Travere Therapeutics
TVTX
$1.56B
| $49.1M | 0.85% | 1,800,500 +475,500 | +36% | +$13M |
|
25
Relmada Therapeutics
RLMD
$37.2M
| $48.9M | 0.84% | 1,525,000 +25,000 | +2% | +$802K |
|